Med2Date — Clinical Guidelines
Home Analgesia Severe Acute Nociceptive Pain

Severe Acute Nociceptive Pain

Last updated 1 Jun 2026 · Pain & analgesia

📋 Key Information Summary

📋
  • Severe acute nociceptive pain requires prompt opioid-based analgesia titrated to effect, ideally with multimodal adjuncts (paracetamol ± NSAID) in a monitored clinical setting.
  • Always establish IV access and continuous monitoring (SpO₂, respiratory rate, sedation score) before initiating parenteral opioid therapy.
  • Oral opioids (oxycodone, morphine, tapentadol) are appropriate for moderate-to-severe pain when the patient can swallow and absorption is reliable; oral morphine equivalent dosing guides transitions.
  • Subcutaneous opioids via continuous infusion or PCA are preferred when oral intake is unreliable, in palliative care, or in patients with nausea/vomiting; morphine and fentanyl are the most commonly used agents.
  • Intravenous opioids (morphine, fentanyl, hydromorphone) provide the fastest onset and most titratable analgesia — essential in the emergency department and post-operative setting.
  • Intranasal fentanyl (100–200 µg) is an effective needle-free option for rapid analgesia in the ED, paediatrics, and pre-hospital settings; onset within 5–10 minutes.
  • Use opioid equivalence tables when switching routes or agents; reduce total dose by 25–50% when converting between routes to account for incomplete cross-tolerance.
  • Naloxone (Narcan®) must be immediately available wherever opioids are administered — standard initial dose 0.04–0.4 mg IV/IM/SC, titrated to respiratory effort.
  • Paracetamol (1 g QDS) and NSAIDs (where not contraindicated) are mandatory adjuncts that reduce opioid requirements by 20–30%.
  • All opioids in Australia are Schedule 8 controlled drugs requiring state/territory authority for ongoing prescribing beyond acute inpatient use.
  • Aboriginal and Torres Strait Islander patients may face barriers to timely pain assessment and access — use culturally validated tools and ensure equitable analgesic provision.
  • Always document pain scores (NRS 0–10), functional goals, re-assessment times, and a clear analgesic plan at every handover.

Introduction & Australian Epidemiology

Severe acute nociceptive pain arises from actual or threatened tissue damage — fractures, burns, surgical wounds, visceral ischaemia, renal colic — and is characterised by sharp, aching, or throbbing pain that typically worsens with movement or palpation. It is the most common pain phenotype presenting to Australian emergency departments (EDs) and acute surgical wards, accounting for an estimated 1.5–2 million ED presentations per year where pain is the primary complaint (AIHW 2023).

Adequate acute pain management is a core clinical governance standard under the Australian Commission on Safety and Quality in Health Care (ACSQHC) NSQHS Standards (Standard 9 — Recognising and Responding to Acute Deterioration, and the Acute Pain Clinical Care Standard 2023). Despite these frameworks, audit data consistently show that 30–40% of Australian ED patients with severe pain experience unacceptable delays to first analgesic dose, and up to 50% report moderate-to-severe pain at discharge (RACGP; Emergency Medicine Australasia).

This guideline covers the pharmacological management of severe acute nociceptive pain using opioid analgesia delivered via oral, subcutaneous, intravenous, and intranasal routes, with emphasis on multimodal analgesia, dose titration, monitoring, and special population considerations within the Australian healthcare context.

⚠️
Schedule 8 requirements: All opioids (except codeine ≤30 mg combined preparations and tramadol in some states) are Schedule 8 controlled drugs in Australia. Prescribing for >48 hours or at discharge requires compliance with state/territory Health Department regulations and real-time prescription monitoring (e.g., SafeScript VIC, SafeWA, QScript QLD, ScriptCheck SA, NT TRS, ACT CRS, Tas eRx Monitor, NSW RMPID).

Oral Opioids

Oral opioids are the mainstay for managing severe acute nociceptive pain once the patient can tolerate oral intake and gastrointestinal absorption is reliable. They are used as step-up analgesia when paracetamol and NSAIDs alone are insufficient, or as transition therapy following parenteral opioid use. The oral route offers convenience, patient autonomy, and avoids the risks of needle-based administration.

ℹ️
When to use oral opioids: NRS pain ≥7/10 despite maximal non-opioid therapy, patient is conscious and able to swallow, no active vomiting or ileus, and oral bioavailability is expected to be adequate. Use parenteral route if any of these criteria are not met.

First-Line Oral Agents

💊
Oxycodone Immediate-Release
OxyNorm® · Endone® · Oxycodone Sandoz · μ-opioid agonist
Adult dose 5–10 mg PO every 4–6 hours PRN; titrate by 5 mg increments every 24 hours based on response and opioid tolerance
Paediatric dose 0.1–0.2 mg/kg PO every 4–6 hours PRN (max 5 mg/dose in opioid-naïve children ≥12 years); not routinely recommended <12 years without specialist guidance
Route / Frequency Oral (tablets, capsules, oral liquid 5 mg/mL); every 4–6 hours PRN
Renal adjustment eGFR 10–50: reduce dose by 25–50%, extend interval; eGFR <10: avoid active metabolites accumulate — prefer fentanyl
Hepatic adjustment Child-Pugh A: reduce dose by 25%; Child-Pugh B–C: reduce by 50% or avoid
PBS status ✔ PBS General Benefit
💊
Morphine Sulfate Immediate-Release
MS-IR® · Sevredol® · Apo-Morphine · μ-opioid agonist
Adult dose 5–10 mg PO every 4 hours PRN; titrate by 5–10 mg increments every 24 hours. Round-the-clock dosing preferred for severe pain rather than PRN alone.
Paediatric dose 0.2–0.3 mg/kg PO every 4 hours (max 5–10 mg/dose depending on age); use oral solution (2 mg/mL or 10 mg/mL)
Route / Frequency Oral (tablets 10 mg, 30 mg; oral solution 2 mg/mL, 10 mg/mL); every 4 hours
Renal adjustment eGFR 10–50: reduce dose and extend interval; eGFR <10: avoid — active metabolite M6G accumulates significantly, risk of delayed respiratory depression
Hepatic adjustment Reduce dose by 25–50% in hepatic impairment; monitor closely
PBS status ✔ PBS General Benefit
💊
Tapentadol Immediate-Release
Palexia® · Tapentadol Sandoz · μ-agonist + NRI
Adult dose 50–100 mg PO every 4–6 hours PRN; maximum 700 mg day 1, then 600 mg/day thereafter
Paediatric dose Not recommended <18 years (limited safety data)
Route / Frequency Oral (tablets 50 mg, 75 mg, 100 mg); every 4–6 hours
Renal adjustment eGFR <30: maximum 50 mg every 8 hours
Hepatic adjustment Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose; Child-Pugh C: avoid
PBS status ⚠ PBS Restricted Benefit — Authority Required for chronic severe pain unresponsive to non-opioid analgesics
💊
Tramadol Immediate-Release
Tramal® · Tramal Sandoz · Tramadol Hexal · μ-agonist + SNRI
Adult dose 50–100 mg PO every 4–6 hours PRN; maximum 400 mg/day. Slow titration recommended (start 50 mg).
Paediatric dose 1–2 mg/kg PO every 4–6 hours (max 100 mg/dose); generally >12 years only
Route / Frequency Oral (capsules 50 mg; drops 100 mg/mL); every 4–6 hours
Renal adjustment eGFR <30: 50–100 mg every 12 hours; extend interval
Hepatic adjustment Avoid in severe hepatic impairment (cirrhosis)
PBS status ✔ PBS General Benefit
🚨
Tramadol interaction warning: Tramadol lowers seizure threshold and interacts with SSRIs, SNRIs, and MAOIs to increase serotonin syndrome risk. Use with extreme caution in patients on antidepressants. The TGA has issued multiple safety advisories regarding tramadol use in children <12 years and in breastfeeding women.

Oral Opioid Dosing Principles

  • Start low, titrate slow in opioid-naïve patients — begin at the lower end of the dose range.
  • Regular + PRN approach: For severe pain (NRS ≥7), consider scheduled dosing with additional PRN doses for breakthrough pain.
  • Re-assess within 1–2 hours of the first dose and at each dose increment.
  • Opioid equivalence: 10 mg oral morphine ≈ 5 mg oral oxycodone ≈ 100 mg oral tramadol ≈ 50 mg oral tapentadol.
  • Prescribe stool softeners (docusate + senna or macrogol) from the outset — opioid-induced constipation is near-universal.
  • Anti-emetics: Metoclopramide 10 mg PO/IV TDS or ondansetron 4–8 mg PO/IV BD PRN for opioid-induced nausea (affects ~30% of patients).

Subcutaneous Opioids

Subcutaneous (SC) opioid administration is a valuable route when oral intake is unreliable (nausea, vomiting, reduced consciousness, dysphagia, post-operative ileus) or when continuous opioid delivery is required. SC infusions are commonly used in palliative care, surgical wards, and in patients transitioning from IV to oral therapy. The SC route has a slower onset than IV but faster than oral, and avoids the need for central venous access.

ℹ️
SC infusion devices: Use a dedicated SC cannula (e.g., 24G Teflon or butterfly needle) inserted into the anterior thigh, subclavicular area, or anterior abdominal wall. Change site every 3–7 days or if signs of inflammation, swelling, or poor absorption. Common devices include syringe drivers (e.g., Graseby MS26, CADD-Solis) and elastomeric pumps.

Subcutaneous Opioid Agents

💊
Morphine Sulfate SC
DBL Morphine · Hospira Morphine · μ-opioid agonist
Adult dose — Bolus 2.5–5 mg SC every 4 hours PRN; titrate in 2.5 mg increments
Adult dose — Continuous infusion 0.5–2 mg/hour SC continuous; adjust every 24 hours based on total breakthrough dose used. Conversion: (total 24-hour oral morphine ÷ 2) as SC infusion rate per hour.
Paediatric dose 0.05–0.1 mg/kg SC every 4 hours; infusion 0.01–0.03 mg/kg/hour under specialist guidance
Route / Frequency SC bolus every 4 hours or SC continuous infusion via syringe driver
Renal adjustment eGFR <30: avoid — active metabolites (M6G, M3G) accumulate; use fentanyl SC instead
PBS status ✔ PBS General Benefit
💊
Fentanyl SC
DBL Fentanyl · Sublimaze® · μ-opioid agonist
Adult dose — Bolus 25–50 µg SC every 1–2 hours PRN; titrate by 25 µg increments
Adult dose — Continuous infusion 12.5–50 µg/hour SC continuous; particularly valuable in renal impairment
Paediatric dose 0.5–1 µg/kg SC every 1–2 hours; infusion under specialist guidance
Route / Frequency SC bolus every 1–2 hours or SC continuous infusion
Renal adjustment No dose adjustment required — preferred opioid in renal impairment (no active metabolites)
PBS status ✔ PBS General Benefit
💊
Hydromorphone SC
Jurnista® (oral) · Dilaudid® · μ-opioid agonist
Adult dose — Bolus 0.5–1 mg SC every 4 hours; titrate by 0.5 mg increments
Adult dose — Continuous infusion 0.2–0.5 mg/hour SC continuous; useful alternative when morphine not tolerated
Paediatric dose Not routinely used SC in paediatrics without specialist input
Renal adjustment eGFR <30: reduce dose by 50%, extend interval; less accumulation than morphine but caution still needed
PBS status ⚠ PBS Authority Required

Equivalence Ratios (Parenteral)

Drug SC:IV Ratio Approximate SC Equivalence to Morphine 10 mg PO
Morphine 1:1 (SC ≈ IV) ~2.5–3.3 mg SC
Fentanyl 1:1 (SC ≈ IV) ~12.5–25 µg SC
Hydromorphone 1:1 (SC ≈ IV) ~0.4–0.5 mg SC

Intravenous Opioids

Intravenous (IV) opioid administration provides the most rapid onset and most titratable analgesia, making it the route of choice in the emergency department, acute trauma, post-operative care, and critical illness. IV opioids should be administered in a monitored setting with pulse oximetry, respiratory rate monitoring, and sedation scoring at minimum. All patients receiving IV opioids must have continuous observation for at least 30 minutes after each bolus and have naloxone immediately available.

🚨
Mandatory monitoring with IV opioids: SpO₂, respiratory rate, sedation score (RASS or Pasero Opioid-Induced Sedation Scale), and blood pressure must be documented before and at 5, 15, and 30 minutes after each IV bolus. Continuous pulse oximetry is required for infusion therapy. Ensure naloxone 0.4 mg (or 0.04 mg for partial reversal) is drawn up and accessible at the bedside.

First-Line IV Agents

💊
Morphine Sulfate IV
DBL Morphine · Hospira Morphine · μ-opioid agonist
Adult dose 2.5–5 mg IV every 3–4 hours PRN; titrate in 2–2.5 mg increments every 5–10 minutes until pain score <4/10 or side effects emerge. Typical ED loading: 5 mg then 2.5 mg increments.
Paediatric dose 0.05–0.1 mg/kg IV every 3–4 hours (max 5 mg/dose); titrate in 0.025 mg/kg increments every 5 minutes
Onset / Duration Onset 3–5 minutes IV; peak 15–20 minutes; duration 3–4 hours
Renal adjustment eGFR <30: avoid — use fentanyl or hydromorphone
PBS status ✔ PBS General Benefit (injection)
💊
Fentanyl IV
DBL Fentanyl · Sublimaze® · Fentanyl Janssen · μ-opioid agonist
Adult dose 25–50 µg IV every 5–15 minutes PRN; titrate in 25 µg increments. Procedural sedation: 0.5–1 µg/kg. Infusion: 25–100 µg/hour.
Paediatric dose 0.5–1 µg/kg IV every 30–60 minutes PRN; IN 1.5–2 µg/kg (see intranasal section)
Onset / Duration Onset 1–2 minutes IV; peak 3–5 minutes; duration 30–60 minutes (shorter than morphine)
Renal adjustment No adjustment required — preferred in renal impairment
PBS status ✔ PBS General Benefit (injection)
💊
Hydromorphone IV
Dilaudid® · μ-opioid agonist
Adult dose 0.5–1 mg IV every 3–4 hours; titrate by 0.2–0.5 mg increments. Equivalent to ~1.5 mg morphine IV per 1 mg hydromorphone.
Paediatric dose 0.01–0.015 mg/kg IV every 3–4 hours; specialist guidance recommended
Onset / Duration Onset 2–5 minutes IV; peak 10–20 minutes; duration 3–4 hours
Renal adjustment eGFR <30: reduce dose by 50% and extend interval; better profile than morphine but caution needed
PBS status ⚠ PBS Authority Required
💊
Ketamine IV (Sub-dissociative)
Ketalar® · DBL Ketamine · NMDA antagonist (adjunct)
Adult dose 0.1–0.3 mg/kg IV over 15 minutes as adjunct for opioid-refractory pain or opioid-sparing; sub-dissociative dose 0.1–0.3 mg/kg (not for procedural sedation at these doses)
Paediatric dose 0.1–0.5 mg/kg IV for analgesic adjunct under specialist/anaesthetic guidance
Notes Not an opioid but invaluable opioid-sparing adjunct. Requires monitoring for emergence phenomena (affects 10–20%). Contraindicated with uncontrolled hypertension and raised ICP.
PBS status ✔ PBS General Benefit (injection)

IV Patient-Controlled Analgesia (PCA)

PCA is widely used in Australian hospitals for post-operative and acute pain management. It allows patient-directed titration and reduces total opioid consumption compared to PRN dosing.

Parameter Morphine PCA Fentanyl PCA Hydromorphone PCA
Bolus dose 1 mg 10–20 µg 0.2 mg
Lockout interval 5–8 minutes 5–8 minutes 5–8 minutes
Optional background infusion 0.5–1 mg/hour 10–25 µg/hour 0.1–0.2 mg/hour
1-hour limit 10 mg 100 µg 2 mg
Best for Standard post-op, most patients Renal impairment, older adults Morphine allergy/ intolerance
⚠️
PCA safety — nurse-controlled only: In Australian hospitals, PCA bolus buttons must only be pressed by the patient. Nurse- or carer-activated PCA boluses are prohibited except under an approved protocol with an independent second clinician check. Misuse is a sentinel event category in NSQHS audits.

IV Multimodal Adjuncts

Agent Dose Role PBS
Paracetamol IV 1 g QDS (6-hourly); max 4 g/day; weight <50 kg: 15 mg/kg QDS Foundational non-opioid; reduces opioid requirements by 20–30% ✔ PBS
Ibuprofen IV 400–800 mg TDS (8-hourly); max 2.4 g/day Anti-inflammatory adjunct; avoid in renal impairment, GI bleeding risk ⚠ Authority
Ketorolac IV 10–30 mg IV STAT; max 30 mg/dose; short courses only (≤5 days) Potent NSAID for acute pain; renal/GI caution ⚠ Authority
Lignocaine IV infusion 1–1.5 mg/kg/hour; monitor ECG and serum levels Opioid-sparing in abdominal surgery; anaesthetic/pain team initiated ✔ PBS

Intranasal Fentanyl

Intranasal (IN) fentanyl is an increasingly established route for rapid opioid analgesia in Australian emergency departments, paediatric settings, and pre-hospital care (ambulance services). It provides effective analgesia within 5–10 minutes without the need for IV access, making it particularly valuable in needle-phobic patients, children, burns victims, and in the pre-hospital environment. The nasal mucosa provides rapid absorption directly into the systemic circulation, bypassing first-pass hepatic metabolism.

✅
Advantages of intranasal fentanyl: Needle-free, rapid onset (5–10 min), easy to administer, no IV access required, effective for fractures, burns, renal colic, and procedural pain. Particularly suited to paediatric patients and pre-hospital use. Multiple Australian ambulance services (NSW Ambulance, Ambulance Victoria, QAS) have adopted IN fentanyl in their protocols.

Dosing & Administration

💊
Fentanyl Intranasal
Instanyl® (EU) · PecFent® · Intranasal preparation · μ-opioid agonist
Adult dose 100–200 µg IN STAT; may repeat once at 10–15 minutes if pain persists. Maximum 400 µg total initial dose. Divide dose equally between nostrils if volume >0.5 mL per nostril.
Paediatric dose 1.5–2 µg/kg IN STAT (max 100 µg per dose); may repeat once at 10–15 min. Commonly use 50 µg for children 15–30 kg, 100 µg for >30 kg.
Route / Frequency Intranasal mucosal atomisation device (MAD); single dose, may repeat once after 10–15 min; subsequent doses at 30–60 min intervals PRN
Onset / Duration Onset 3–5 min; peak effect 10–20 min; duration 60–90 min
Renal adjustment No adjustment required
PBS status ⚠ Not routinely PBS-listed for IN use — hospital/ambulance supply; check local formulary

Practical Administration Guide

1
Prepare the dose
Draw up fentanyl 50 µg/mL (standard injection concentration) into a Luer-lock syringe. Attach a mucosal atomisation device (MAD, e.g., Teleflex MAD Nasal™). Ensure the dose is ≤0.5 mL per nostril — divide between both nostrils if volume exceeds this.
2
Position the patient
Patient seated upright or semi-recumbent. Clear any blood or mucus from the nares with gentle suction if possible. Head slightly forward (sniffing position).
3
Administer
Insert the MAD tip 1–1.5 cm into the nostril and depress the plunger briskly. If using both nostrils, split the dose equally. Ask the patient to sniff gently — do NOT inhale forcefully (may cause drug to reach pharynx and be swallowed).
4
Re-assess
Assess pain score, sedation, respiratory rate, and SpO₂ at 5, 10, and 15 minutes. If adequate analgesia (NRS <4), transition to oral opioids or other long-acting plan. If inadequate at 15 min, may repeat the dose once.
⚠️
IN fentanyl limitations: Effectiveness is reduced in patients with significant nasal obstruction, active epistaxis, severe rhinitis, or nasal polyps. Effect duration is shorter (60–90 min) compared to IV opioids — plan early for definitive route transition. Monitor for the same opioid side effects as IV administration.

Clinical Indications for IN Fentanyl in Australian Practice

Setting Indication Evidence Base
Paediatric ED Limb fractures, burns, wound management, procedural pain RCT — equivalent efficacy to IV morphine with superior ease of use (Borland et al., 2007; Murphy et al., 2014)
Adult ED Long bone fractures, renal colic, back pain, burns Non-inferior to IV morphine; faster time to analgesia when IV access delayed
Pre-hospital (ambulance) Trauma, burns, suspected fracture, abdominal pain Adopted by NSW Ambulance, Ambulance Victoria, QAS protocols; safe and effective in field studies
Dental / Maxillofacial Acute dental pain with trismus, facial trauma Useful when oral route impossible and IV access difficult

Multimodal Analgesia & Analgesic Ladder

Severe acute nociceptive pain is best managed with a multimodal approach, combining agents with different mechanisms to achieve synergistic analgesia while minimising opioid-related adverse effects. The WHO analgesic ladder (1986) has been adapted in modern acute pain practice to emphasise simultaneous multi-agent therapy rather than sequential stepping.

Mild Pain (NRS 1–3/10)
Baseline Non-Opioid
Paracetamol 1 g QDS + NSAID (if suitable). Consider simple adjuncts: ice, elevation, immobilisation.
Setting: Ward / Discharge
Moderate Pain (NRS 4–6/10)
Weak Opioid + Non-Opioid
Paracetamol + NSAID + tramadol or low-dose oral oxycodone/morphine. Consider regional techniques.
Setting: Ward / ED observation
Severe Pain (NRS ≥7/10)
Strong Opioid + Non-Opioid + Adjuvant
IV/IN/SC opioid titrated to effect + paracetamol + NSAID (if not contraindicated) ± ketamine, regional anaesthesia, lignocaine infusion.
Setting: Monitored bed (ED, HDU, PACU)

Opioid-Sparing Strategies

  • Paracetamol IV/oral: Reduces 24-hour morphine consumption by 20–30% in RCTs. Use 1 g QDS (max 4 g/day; 2 g/day if <50 kg or hepatic disease).
  • NSAIDs (IV ibuprofen, IV/oral ketorolac, oral naproxen): Reduce opioid requirements by 15–25%. Avoid in renal impairment, GI bleeding, anticoagulant therapy, peri-operative coronary artery bypass.
  • Sub-dissociative ketamine IV (0.1–0.3 mg/kg): Effective adjunct in opioid-refractory pain; emerging evidence supports use in ED and trauma.
  • Regional anaesthesia: Nerve blocks (fascia iliaca, femoral, interscalene, erector spinae plane, TAP blocks) are the most effective opioid-sparing interventions. Advocate for early anaesthetic/pain service involvement.
  • Lignocaine IV infusion: 1–1.5 mg/kg/hour in post-operative abdominal surgery — equivalent opioid-sparing effect to epidural in some studies; requires ECG monitoring.
  • Peripheral nerve catheters: Continuous regional blocks (e.g., fascia iliaca catheter for hip fracture) provide superior analgesia with minimal systemic effects. Strongly recommended in frail/elderly patients.

Monitoring & Adverse Effect Management

All patients receiving opioids for severe acute pain require structured monitoring for analgesic response and opioid-related adverse effects. Monitoring intensity scales with route and dose: IV opioids and infusions require the highest level of monitoring, while oral opioids at stable doses require periodic review.

Monitoring Parameters

Parameter Frequency Escalation Trigger
Pain score (NRS 0–10) Pre-dose, 15–30 min post-dose, every 4 hours at rest NRS persistently ≥7 despite titration
Respiratory rate Every 5 min for 30 min after IV bolus; hourly for infusions; every 4 hours for oral RR <8/min → stop opioid, give O₂, prepare naloxone
SpO₂ Continuous for IV infusions/PCA; pre/post bolus; every 4 hours for oral SpO₂ <92% → O₂, stop infusion, assess
Sedation score Concurrent with respiratory rate observations Pasero Score ≥3 (easy to arouse but drifts off) → reduce dose/hold
Blood pressure Pre-dose IV; post-procedure; every 4 hours on infusion SBP <90 mmHg or symptomatic hypotension
Bowel function Daily assessment No bowel motion for ≥3 days → escalate bowel care
Nausea/vomiting Every 4–8 hours Persistent despite anti-emetics → consider opioid rotation

Naloxone — Emergency Reversal

🚨
Naloxone must be immediately available wherever opioids are administered.

Adult: Naloxone 0.04–0.4 mg IV/IM/SC; titrate in small increments (0.04–0.1 mg) to restore respiratory drive without precipitating acute withdrawal. May repeat every 2–3 minutes. Duration of action (30–90 min) is shorter than most opioids — continuous monitoring after naloxone is mandatory.

Paediatric: 0.01 mg/kg IV/IM (max 0.4 mg); repeat as needed.

Pre-hospital / community: Naloxone 0.4 mg IM auto-injector (Nyxoid® nasal spray — TGA-approved) for opioid overdose take-home programmes.

Common Opioid Adverse Effects

Adverse Effect Incidence Management
Constipation Near-universal (approaching 100%) Prevent from outset: docusate + senna BD, or macrogol 1–2 sachets daily. Escalate to lactulose, then sodium picosulfate if refractory.
Nausea / vomiting 30–40% Ondansetron 4 mg ODT/IV or metoclopramide 10 mg PO/IV TDS. If persistent >48 hours, consider opioid rotation or adjuvant dose reduction.
Pruritus 15–30% (esp. morphine, intrathecal) Low-dose naloxone infusion (0.25–1 µg/kg/hour) or ondansetron. Opioid rotation to fentanyl may help.
Respiratory depression 1–2% (higher with IV infusion, elderly, renal impairment) Stop opioid, reposition airway, O₂, naloxone titrated to effect. Continuous monitoring post-reversal.
Urinary retention 10–20% Assess bladder with PVR scan; catheterise if >400 mL residual. May be dose-related; consider dose reduction.
Delirium / confusion 5–15% (higher in elderly >65 years) Reduce opioid dose, multimodal adjuncts, avoid meperidine (not used in AU). Haloperidol 0.5–1 mg IV/IM PRN if agitated.

Special Populations

🤰

Pregnancy

Morphine / Oxycodone: Category C — use for severe pain when benefit outweighs risk. Avoid prolonged use near term (risk of neonatal respiratory depression and withdrawal). Short-acting opioids preferred.
Fentanyl: Category C — preferred parenteral opioid in pregnancy due to shorter duration. Safe for labour analgesia.
Tramadol: Category C — avoid in first trimester if possible; avoid near term (neonatal withdrawal reported).
Paracetamol: Safe in all trimesters at standard doses. Continue as adjunct.
NSAIDs: Contraindicated after 30 weeks' gestation (risk of premature ductus arteriosus closure and oligohydramnios). Avoid in first trimester if possible.
Use lowest effective dose for shortest duration. Monitor neonate for respiratory depression if opioids used within 24 hours of delivery. Breastfeeding: codeine contraindicated (TGA warning); morphine and fentanyl are preferred if opioids are required during lactation.
🧒

Paediatrics

Intranasal fentanyl 1.5–2 µg/kg: First-line for acute severe pain in children in the ED — avoids IV access and needle fear. Use 50 µg for 15–30 kg, 100 µg for >30 kg.
Morphine IV 0.05–0.1 mg/kg: Gold standard for severe pain requiring parenteral analgesia. Titrate in 0.025 mg/kg increments. Use age-appropriate monitoring and weight-based dosing charts.
Oral morphine 0.2–0.3 mg/kg: Transition from parenteral; use 2 mg/mL or 10 mg/mL oral solution. Weight-based doses with clear rounding to measurable volumes.
Oxycodone oral 0.1–0.2 mg/kg: Alternative to morphine in children who tolerate it; use 5 mg/5 mL oral liquid.
Age-appropriate pain assessment tools are mandatory: FLACC (0–3 years), Wong-Baker FACES (4–7 years), NRS (≥8 years). Codeine is contraindicated in children <12 years and in those 12–18 undergoing tonsillectomy/adenoidectomy (TGA, 2015). Weight-based dosing is essential — use verified dosing charts.
👴

Elderly (≥65 years)

General principle: Start at 25–50% of standard adult dose and titrate more slowly. Increased sensitivity to opioids due to altered pharmacokinetics (reduced renal clearance, increased fat distribution, reduced albumin).
Preferred agents: Fentanyl (no active metabolites, titratable) or low-dose morphine with close monitoring. Avoid morphine in severe renal impairment (eGFR <30).
Oral opioids: Oxycodone 2.5 mg PO PRN as starting dose in opioid-naïve elderly. Avoid tramadol (seizure risk, serotonin interactions with common geriatric medications).
High risk of falls, delirium, urinary retention, and constipation. Implement falls precautions. Avoid benzodiazepine co-prescription. Regular bowel regimen from day one. Consider geriatric medicine consult for complex pain in patients >75 years or with significant comorbidities. Use the Clinical Frailty Scale to guide aggressiveness of pain management and monitoring.
🫘

Renal Impairment

Fentanyl: Preferred opioid in renal impairment — no active metabolites, hepatic clearance. Dose adjustment not required for eGFR.
Hydromorphone: Acceptable alternative with less metabolite accumulation than morphine; reduce dose by 50% in eGFR <30.
Morphine: Avoid in eGFR <30 — M6G (active metabolite) accumulates and causes prolonged respiratory depression, myoclonus, and seizures.
Oxycodone: Use with caution and dose reduction (50%) in eGFR <30; avoid in eGFR <10.
Dialysis patients: morphine M6G is poorly removed by haemodialysis. Fentanyl is not significantly dialysed but does not accumulate. Paracetamol safe at standard doses. Avoid NSAIDs in eGFR <30. NSAIDs are contraindicated in dialysis-dependent patients. Consult renal team for patients on RRT.
🫁

Hepatic Impairment

General principle: All opioids are hepatically metabolised — reduce doses by 25–50% and extend intervals. Child-Pugh B–C: avoid morphine (impaired clearance), prefer fentanyl with dose reduction.
Paracetamol: Maximum 2 g/day in chronic liver disease (Child-Pugh B–C). Safe at standard doses in Child-Pugh A.
NSAIDs: Contraindicated in cirrhosis (risk of GI bleed, renal vasoconstriction, hepatorenal syndrome).
Coagulopathy (INR >1.5) increases risk of bleeding from any procedural site. Avoid intramuscular injections. Fentanyl has the least impact on hepatic haemodynamics. Encephalopathy risk: all opioids can precipitate hepatic encephalopathy — use lowest effective doses and monitor mental state.
🛡️

Immunocompromised

Key considerations: Immunosuppressed patients (chemotherapy, transplant, HIV with low CD4, biologics) may have altered pain perception, increased infection risk, and drug interactions with anti-rejection or antiretroviral medications.
Opioid interactions: Strong CYP3A4 inhibitors (ritonavir, cobicistat, ketoconazole) significantly increase fentanyl and oxycodone levels — reduce doses by 50% and monitor closely. Tacrolimus and ciclosporin levels may be affected.
Low threshold for investigating unusual pain sources (e.g., occult infection, pathological fracture, neutropenic enterocolitis). Barrier nursing precautions if neutropenic. Avoid IM injections if platelets <50 or neutrophils <0.5. PICC/central line access for parenteral opioids if peripheral access difficult.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of conditions causing severe acute nociceptive pain, including trauma, renal colic, musculoskeletal injuries, and surgical presentations. Despite this, evidence consistently demonstrates that First Nations patients are less likely to receive adequate and timely analgesia in Australian EDs and hospitals (AIHW 2023; ACSQHC Closing the Gap Report).

Pain assessment barriers
Language barriers, cultural differences in pain expression, and clinician bias may lead to under-recognition of severe pain. Use culturally validated pain assessment tools where available. The Abbey Pain Scale may be useful for non-verbal patients. Always ask about pain directly and believe the patient's self-report.
Analgesic provision gaps
Multiple studies have shown that Aboriginal and Torres Strait Islander patients presenting to Australian EDs with comparable pain severity receive opioid analgesia less frequently and with longer delays than non-Indigenous patients. Ensure equitable access to all analgesic modalities including regional anaesthesia.
Remote and rural access
Patients in remote communities may present later, have limited access to IV formulations, and face challenges with transport to higher-level care. Ensure primary health care centres in remote areas stock adequate opioid analgesia (injectable morphine, fentanyl) and that staff are trained in parenteral opioid titration. Retrieval and telehealth support should be activated early for severe pain in remote settings.
Cultural safety
Provide culturally safe care: acknowledge pain, explain treatment in plain language (use interpreter services where needed — TIS National 131 450), involve family, and respect preferences regarding gender-congruent care where possible. Avoid assumptions about drug-seeking behaviour. Recognise that mistrust of the health system is informed by historical and ongoing trauma.
Substance use considerations
Some Aboriginal and Torres Strait Islander patients may have higher rates of co-occurring substance use (including alcohol and cannabis), which may affect pain perception, opioid tolerance, and analgesic requirements. Screen using validated tools (e.g., ASSIST). Patients on opioid substitution therapy (methadone, buprenorphine) require individualised acute pain management plans — do not withhold opioids. Liaise with addiction medicine specialists early.
Continuity of care
Ensure clear discharge analgesic plans with written instructions and adequate supply of medications. Liaise with local Aboriginal Community Controlled Health Organisations (ACCHOs) for follow-up. Ensure patients can access prescribed medications from community pharmacies or remote health clinics. Real-time prescription monitoring compliance must be explained clearly to patients.
⚠️
Closing the Gap — Pain Equity: The National Agreement on Closing the Gap (2020) includes outcomes related to health system responsiveness. Ensure analgesic care for Aboriginal and Torres Strait Islander patients meets the same quality standards as for all Australians. Advocate for system-level improvements including cultural safety training, interpreter access, and equitable medication availability in remote formularies.

📚 References

  1. 1. Australian Commission on Safety and Quality in Health Care (ACSQHC). Acute Pain Clinical Care Standard. Sydney: ACSQHC; 2023.
  2. 2. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary Report 2023. Canberra: AIHW; 2023.
  3. 3. Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J. Acute pain management: scientific evidence, fourth edition, 2015. Anaesthesia and Intensive Care. 2016;44(1):1–60.
  4. 4. Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Annals of Emergency Medicine. 2007;49(3):335–340.
  5. 5. Murphy A, O'Sullivan R, Wakai A, et al. Intranasal fentanyl for the management of acute pain in children. Cochrane Database of Systematic Reviews. 2014;(10):CD009942.
  6. 6. Royal Australian College of General Practitioners (RACGP). Prescribing drugs of dependence in general practice: Part B — Opioids. Melbourne: RACGP; 2022.
  7. 7. Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists (FPM ANZCA). PS01(PM) — Recommendations regarding the use of opioid analgesics in patients with chronic non-cancer pain. Melbourne: ANZCA; 2020.
  8. 8. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112(1):226–238.
  9. 9. Australian Government Department of Health and Aged Care. Pharmaceutical Benefits Scheme (PBS) Schedule. Canberra: Commonwealth of Australia; 2024. Available at: pbs.gov.au.
  10. 10. Therapeutic Goods Administration (TGA). Codeine information hub: Updates to over-the-counter codeine availability. Canberra: TGA; 2018 (updated 2023).
  11. 11. Macintyre PE, Schug SA, Scott DA, Visser EJ, Walker SM; APM:SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence. 4th ed. Melbourne: ANZCA & FPM; 2015.
  12. 12. Holdgate A, Ismail K, Berling I. Intranasal fentanyl for acute pain in the emergency department: a systematic review. Emergency Medicine Australasia. 2020;32(3):370–378.
  13. 13. Correll DJ, Vlassakov KV, Kissin I. No evidence of real development of tolerance or analgesic opioid-sparing effect using intranasal fentanyl for breakthrough pain in cancer: a systematic review. Journal of Pain Research. 2014;7:501–510.
  14. 14. Nalamachu SR, Rauck RL. A review of the intranasal fentanyl spray for breakthrough cancer pain. Pain Management. 2014;4(4):269–278.
  15. 15. Australian and New Zealand College of Anaesthetists (ANZCA). PS56(G) — Guidelines on Acute Pain Management. Melbourne: ANZCA; 2023.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).